Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Kenya’s anti-counterfeit legislation, India protest (Afro-IP)

Cepham – US: CAFC: Another ‘bright-line’ rule from the Federal Circuit; double jeopardy – later developments can overcome double patenting: Takeda Pharmaceutical Co v Doll (Patent Docs) (Patent Baristas)

‘Green Gold Rush’ documentary about bioprospecting and indigenous peoples (IP Dragon)

UNITAID and Clinton HIV/AIDS Initiative make deal with generic drug makers to cut prices for off-patent HIV/AIDS drugs (Managing Intellectual Property)

Argentina: Maintaining data exclusivity (International Law Office) (IP tango)

China: ‘A new dawn for China healthcare… or grand theft IP? (IP Dragon)

EU: Anti-patent rally; criticism of practice of patenting biological processes – Munich (Intellectual Property Watch) (Patenting Lives)

EU: Fordham IP conference: EU pharma sector enquiry slammed (Managing Intellectual Property)

Hungary: Board of Appeal: Medical preparations not similar to cosmetics (International Law Office)

India: The ‘Mashelkar Committee Report’ on pharma patenting resurfaces! (Spicy IP)

India: Assessing India’s innovation climate (Biotech Blog)

Kenya’s anti-counterfeit legislation, India protest (Afro-IP)

Mexico: Pharmaceutical trade marks: the Health Law pitfall for applicants (International Law Office)

US: BIO IP Counsels’ Committee: Q Todd Dickinson and E Anthony Figg on patent reform (Patent Docs)

US: Amgen VP makes case for longer exclusivity period in follow-on biologics legislation (Patent Docs)

Cepham – US: CAFC: Another ‘bright-line’ rule from the Federal Circuit; double jeopardy – later developments can overcome double patenting: Takeda Pharmaceutical Co v Doll (Patent Docs) (Patent Baristas)

Cozaar (Losartan) – UK: IPO refuses E I du Pont de Nemours & Co’s application for pediatric extension for Losartan SPC (The SPC Blog)

Evista (Raloxifene) – Lilly granted preliminary injunction to prevent launch generic Raloxifene by Teva (SmartBrief) (SmartBrief)

Glivec (Imatinib) – India rejects Novartis’ application to patent Glivec’s second variant (GenericsWeb)

Lexapro (Escitalopram) – Netherlands: An insight into Dutch costs: ratiopharm, Tiefenbacher and Centrafarm et al v Lundbeck (PatLit)

Pristique (O-desmethylvenlafaxine) – US: Sepracor and Wyeth set out to find who invented Pristiq drug first (Patent Baristas) (GenericsWeb)

Pulmicort (Budesonide) – US: Apotex preliminarily barred from selling generic version of AstraZeneca’s Pulmicort (GenericsWeb)

Rythmol (Propafenone) – US: Par Pharmaceutical enters into agreement with Reliant Pharmaceuticals to settle patent litigation over Rythmol (GenericsWeb)

Topamax (Topiramate) – US: FDA resolves pre-MMA/post-MMA 180-day exclusivity regime will apply in ‘MMA straddle’ cases (FDA Law Blog)

Xeloda (Capecitabine) – US: Hoffman-La Roche sues Mylan in connection with generic Xeloda ANDA (GenericsWeb)